Phase 2 results in inflammatory bowel disease hinted the therapy could be more potent than similar medicines from Merck and ...

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Sanofi SA’s (NASDAQ:SNY) Phase 2b RELIEVE UCCD study met its primary ...

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s diseasePrimary endpoints met in ...

Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today announced that the RELIEVE UCCD phase 2b study met its primary endpoints in patients with ulcerative ...

When it comes to blood tests, doctors suggest you speak about these six with your primary healthcare provider.

City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center named top 5 in the nation for cancer by U.S. News ...

Teva Pharmaceuticals and Sanofi announced positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn ...

The search for effective therapies in ulcerative colitis, a chronic inflammatory condition affecting the colon and rectum with a relapsing–remitting course, has been a long and challenging journey, ...

US affiliate and partner Sanofi (SNY) said Tuesday that a phase 2b study of Teva's investigational duvakitug drug to treat ulcerative colitis and Crohn's disease met its primary endpoints. Ulcerative ...